ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Drugs, Investigational

Also written as “Investigational drug”, “Investigational new drug, company code: BGG492” and “TimoD implant”.

Its studies are mostly in Keratosis, Actinic · Glaucoma · Burns · Glaucoma, Open-Angle · Nervous System Diseases, led by 7 companies.

Drug pageDrugs, Investigational: every studyMany companies study it; this page follows only the 10 they lead. All 14 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 17, 202510 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EyeD Pharmaits history only21 open or runningphase 2since Jun 17, 2025Mar 13, 2024Jan 2027phase 2 · NCT07036510
Novartisits history only20 open or runningphase 2since Apr 23, 2009Apr 23, 2009none ahead
Pfizer20 open or runningphase 2since May 2, 2002May 2, 2002none ahead
Bristol-Myers Squibbits history only10 open or runningphase 2since Jun 26, 2002Jun 26, 2002none ahead
Merckits history only10 open or runningphase 3since Aug 25, 2000Aug 25, 2000none ahead
Skingenixits history only11 open or runningphase 2since Feb 14, 2011Feb 14, 2011Dec 31, 2026phase 2 · NCT01297400
Sun Pharmaceutical Industriesits history only11 open or runningphase 1since Jul 22, 2026Jul 22, 2026Dec 2026phase 1 · NCT07729579

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 2, 2002First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT00034957 · United States
  2. May 8, 2002Phase 1 study in Multiple MyelomaNCT00036140 · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00036140Multiple Myeloma · United States1Completed
NCT00034957Carcinoma, Non-Small-Cell Lung · United States2CompletedOct 2002

How it is read

Names in the registry

  • “Investigational drug”, 5 entries
  • “Investigational new drug, company code: BGG492”, 3 entries
  • “TimoD implant”, 2 entries
  • “Investigational Drug, MW-III”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.